02:06 PM EDT, 07/31/2024 (MT Newswires) -- Achieve Life Sciences ( ACHV ) got the US Food and Drug Administration's Breakthrough Therapy Designation for cytisinicline to treat for e-cigarette or vaping nicotine dependence.

The designation is based on results from the phase 2 trial that showed treatment with cytisinicline more than doubled the odds of quitting e-cigarettes compared with placebo,

Achieve Life Sciences ( ACHV ) said Wednesday in a statement.

Achieve Life Sciences ( ACHV ) plans to hold a meeting with the FDA under the Breakthrough Therapy Designation before the end of 2024.

The company's shares rose 3.4% in recent trading Wednesday.

Price: 5.10, Change: +0.17, Percent Change: +3.35